Clinical News-CliniExpert

Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

GAITHERSBURG, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the

GSK and CureVac Develop Next-Generation mRNA Vaccine Against COVID-19

London, UK / Tuebingen, Germany / Boston, USA - February 3, 2021 -- GlaxoSmithKline plc (LSE / NYSE: GSK) and CureVac NV (Nasdaq: CVAC) today announce a new € 150 million collaboration that builds on

Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2021 -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Singapore H

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

NEW YORK--(BUSINESS WIRE) February 3, 2021 -- Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Mye

COVID-19 Vaccine AstraZeneca Confirms 100% Protection Against Severe Disease, Hospitalisation and Death in the Primary Analysis of Phase III Trials

3 February 2021 -- The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and

Sputnik V’s Efficacy in Fighting COVID-19 is Validated by Internationally Peer Reviewed Data Published in The Lancet

Moscow, February 2, 2021 -- The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF, Rus

Data Presented at WORLDSymposium Reinforces Robust Rare Disease Pipeline and Highlights Additional Clinical Data for Investigational Avalglucosidase Alfa in Pompe Disease

February 2, 2021 -- Data with investigational enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) will be featured as platform a

Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla (apremilast)

PRINCETON, N.J.--(BUSINESS WIRE) February 2, 2021 -- Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models

CureVac and Rentschler Biopharma to Ramp Up Production of COVID-19 Vaccine CVnCoV

Tübingen / Laupheim, Germany and Boston / Milford, MA, USA, February 1, 2021 -- CureVac NV (Nasdaq: CVAC), a biopharmaceutical company engaged in clinical trials to develop a new class of drugs based

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

CHENGDU, China, February 1, 2021 -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

EMERYVILLE, CALIFORNIA and CHENGDU, CHINA, February 1, 2021 -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vac